vs
ASP Isotopes Inc.（ASPI）与Personalis, Inc.（PSNL）财务数据对比。点击上方公司名可切换其他公司
Personalis, Inc.的季度营收约是ASP Isotopes Inc.的1.0倍（$17.3M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 3.2%），Personalis, Inc.自由现金流更多（$-22.3M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Personalis, Inc.是一家专注于肿瘤领域先进基因组学解决方案的精准医疗企业，开发专有基因组测序及数据分析平台，为生物制药合作伙伴的免疫疗法研发、临床机构的个性化癌症诊疗提供支持，业务覆盖北美、欧洲及亚太核心市场。
ASPI vs PSNL — 直观对比
营收规模更大
PSNL
是对方的1.0倍
$16.7M
营收增速更快
ASPI
高出1292.4%
3.2%
自由现金流更多
PSNL
多$25.1M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $17.3M |
| 净利润 | — | $-23.8M |
| 毛利率 | 12.5% | 11.0% |
| 营业利润率 | — | -145.7% |
| 净利率 | — | -137.3% |
| 营收同比 | 1295.7% | 3.2% |
| 净利润同比 | -586.8% | -45.0% |
| 每股收益（稀释后） | — | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIPSNL
| Q4 25 | $16.7M | $17.3M | ||
| Q3 25 | $4.9M | $14.5M | ||
| Q2 25 | — | $17.2M | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | — | $16.8M | ||
| Q3 24 | — | $25.7M | ||
| Q2 24 | — | $22.6M | ||
| Q1 24 | — | $19.5M |
净利润ASPIPSNL
| Q4 25 | — | $-23.8M | ||
| Q3 25 | $-12.9M | $-21.7M | ||
| Q2 25 | — | $-20.1M | ||
| Q1 25 | — | $-15.8M | ||
| Q4 24 | — | $-16.4M | ||
| Q3 24 | — | $-39.1M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | — | $-13.0M |
毛利率ASPIPSNL
| Q4 25 | 12.5% | 11.0% | ||
| Q3 25 | 8.7% | 13.2% | ||
| Q2 25 | — | 27.6% | ||
| Q1 25 | — | 35.0% | ||
| Q4 24 | — | 27.1% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 28.1% |
营业利润率ASPIPSNL
| Q4 25 | — | -145.7% | ||
| Q3 25 | -306.1% | -160.7% | ||
| Q2 25 | — | -126.7% | ||
| Q1 25 | — | -85.9% | ||
| Q4 24 | — | -107.8% | ||
| Q3 24 | — | -55.9% | ||
| Q2 24 | — | -74.8% | ||
| Q1 24 | — | -96.7% |
净利率ASPIPSNL
| Q4 25 | — | -137.3% | ||
| Q3 25 | -263.7% | -149.4% | ||
| Q2 25 | — | -116.6% | ||
| Q1 25 | — | -76.4% | ||
| Q4 24 | — | -97.8% | ||
| Q3 24 | — | -152.0% | ||
| Q2 24 | — | -56.7% | ||
| Q1 24 | — | -66.4% |
每股收益（稀释后）ASPIPSNL
| Q4 25 | — | $-0.26 | ||
| Q3 25 | $-0.15 | $-0.24 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.64 | ||
| Q2 24 | — | $-0.24 | ||
| Q1 24 | — | $-0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $240.0M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $261.2M |
| 总资产 | $498.0M | $334.2M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIPSNL
| Q4 25 | $333.3M | $240.0M | ||
| Q3 25 | $113.9M | $150.5M | ||
| Q2 25 | — | $173.2M | ||
| Q1 25 | — | $185.7M | ||
| Q4 24 | — | $185.0M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $87.0M | ||
| Q1 24 | — | $95.4M |
总债务ASPIPSNL
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPIPSNL
| Q4 25 | $204.2M | $261.2M | ||
| Q3 25 | $74.1M | $171.4M | ||
| Q2 25 | — | $190.8M | ||
| Q1 25 | — | $207.3M | ||
| Q4 24 | — | $203.0M | ||
| Q3 24 | — | $166.8M | ||
| Q2 24 | — | $112.3M | ||
| Q1 24 | — | $120.7M |
总资产ASPIPSNL
| Q4 25 | $498.0M | $334.2M | ||
| Q3 25 | $225.9M | $242.8M | ||
| Q2 25 | — | $258.7M | ||
| Q1 25 | — | $273.3M | ||
| Q4 24 | — | $270.3M | ||
| Q3 24 | — | $239.9M | ||
| Q2 24 | — | $185.5M | ||
| Q1 24 | — | $195.3M |
负债/权益比ASPIPSNL
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-22.3M |
| 自由现金流率自由现金流/营收 | -284.7% | -128.7% |
| 资本支出强度资本支出/营收 | 57.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-79.5M |
8季度趋势，按日历期对齐
经营现金流ASPIPSNL
| Q4 25 | $-37.8M | $-22.2M | ||
| Q3 25 | $-8.9M | $-21.8M | ||
| Q2 25 | — | $-12.9M | ||
| Q1 25 | — | $-18.0M | ||
| Q4 24 | — | $-7.8M | ||
| Q3 24 | — | $-6.2M | ||
| Q2 24 | — | $-10.7M | ||
| Q1 24 | — | $-20.4M |
自由现金流ASPIPSNL
| Q4 25 | $-47.4M | $-22.3M | ||
| Q3 25 | $-12.0M | $-23.4M | ||
| Q2 25 | — | $-13.2M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | — | $-9.0M | ||
| Q3 24 | — | $-6.4M | ||
| Q2 24 | — | $-10.7M | ||
| Q1 24 | — | $-20.5M |
自由现金流率ASPIPSNL
| Q4 25 | -284.7% | -128.7% | ||
| Q3 25 | -245.5% | -161.6% | ||
| Q2 25 | — | -76.9% | ||
| Q1 25 | — | -99.4% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -25.1% | ||
| Q2 24 | — | -47.6% | ||
| Q1 24 | — | -105.1% |
资本支出强度ASPIPSNL
| Q4 25 | 57.9% | 0.4% | ||
| Q3 25 | 64.4% | 11.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
PSNL
| Population Sequencing | $11.8M | 68% |
| Related Party | $5.4M | 31% |
